Caplin Point Laboratories Limited has officially acquired Neoethicals Chile SpA, a pharmaceutical marketing and distribution company based in Chile. The acquisition, conducted through Caplin Point Far East Limited, a wholly owned subsidiary of Caplin Point, was completed on April 1, 2025.

This strategic investment marks a significant expansion for Caplin Point Laboratories in the Latin American pharmaceutical market, strengthening its direct sales and distribution operations in Chile.

Key Details of the Acquisition

1. Name of the Target Entity & Business Overview

The acquired entity, Neoethicals Chile SpA, specializes in the marketing and distribution of pharmaceutical products. It has been distributing Caplin Point’s products in Chile, making the acquisition a natural progression for establishing a stronger local presence.

• Turnover for 2024: 278,565,412 Chilean Pesos (Approx. USD 295,222)

• Turnover for 2023: 49,995,906 Chilean Pesos (Approx. USD 59,585)

• Turnover for 2022: Nil

• Incorporation Date: March 31, 2015

2. Strategic Purpose & Rationale

The acquisition is aligned with Caplin Point Laboratories’ expansion strategy in Latin America, allowing direct access to the Chilean pharmaceutical market.

• Neoethicals Chile SpA will now function as the front-end entity for Caplin Point’s direct sales, marketing, and distribution in Chile.

• This move ensures greater control over the supply chain, boosting efficiency and profitability in the region.

3. Consideration & Financial Terms

• Total Shares Acquired: 3,000 shares

• Acquisition Price: Face value of One Thousand Chilean Peso per share (USD 3,000 total).

• Mode of Payment: Cash payment through banking channels by Caplin Point Far East Limited.

4. Related Party & Shareholding Changes

• Post-acquisition, Neoethicals Chile SpA becomes a wholly owned subsidiary of Caplin Point Far East Limited and a step-down subsidiary of Caplin Point Laboratories Limited.

• The acquisition does not involve Caplin Point’s promoter group. However, post-acquisition, Neoethicals Chile SpA becomes a related party of the company.

5. Government & Regulatory Approvals

• No prior regulatory approvals were required for this acquisition.

• The transaction was completed as per the SEBI Listing Regulations and has been disclosed under Regulation 30.

Impact on Caplin Point Laboratories

The acquisition of Neoethicals Chile SpA strengthens Caplin Point’s direct sales capabilities in the Chilean pharmaceutical market, reinforcing its commitment to expanding its global footprint.

• Chile presents a growing pharmaceutical market, and by directly operating in the region, Caplin Point aims to capture a larger market share.

• The acquisition at face value reflects a strategic move to control distribution operations, eliminating dependency on third-party vendors.

Conclusion

Caplin Point Laboratories' investment in Neoethicals Chile SpA represents a calculated expansion into the Latin American pharmaceutical sector. With the acquisition now complete, the company is set to leverage its enhanced market position to drive growth and revenue generation in Chile.

This move demonstrates Caplin Point’s long-term vision for global expansion, reaffirming its commitment to strengthening international sales and distribution networks.

The Current active IPO are Infonative Solutions Limited,Spinaroo Commercial Limited,Retaggio Industries Limited.

The Closed IPOs are  Identixweb Limited, ATC Energies System Limited, Shri Ahimsa Naturals Limited.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in .Choice Broking FinX